BioStock: Ultimovacs' malignant melanoma study fully recruited

Norwegian biotech Ultimovacs shows progress in the clinical trial of malignant melanoma despite challenges caused by the pandemic. The clinical-stage leader in immune-stimulatory cancer vaccines has now reached the recruitment goal in the INITIUM phase II trial of UV1. The study provides randomised data on the effectiveness of UV1 as an add-on to standard-of-care treatment. Topline progression-free survival data is expected in H1 2023.

Read the article at biostock.se:

https://www.biostock.se/en/2022/07/ultimovacs-malignant-melanoma-study-fully-recruited/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/